HUN Huntsman CORP
Chemicals & Allied Products · NYSE · SEC CIK 1307954 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.7%
TTM net income YoY-111.5%
TTM EPS YoY-112.1%
Revenue 3-yr CAGR-8.5%
Net income 3-yr CAGR—
Margins
Gross margin12.9%
Operating margin-3.3%
Net margin-5.8%
FCF margin2.4%
EBITDA margin1.8%
Returns
ROE-11.8%
ROA-4.6%
ROIC (approx.)-3.3%
Asset turnover0.79x
Leverage & solvency
Liabilities / assets59.3%
Debt / equity0.77x
Current ratio1.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.93x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.68B | $6.04B | $6.11B | $8.02B | $7.67B |
| Cost of revenue | $4.93B | $5.17B | $5.21B | $6.48B | $6.09B |
| Gross profit | $751.00M | $866.00M | $906.00M | $1.55B | $1.58B |
| R&D expense | $120.00M | $121.00M | $115.00M | $125.00M | $135.00M |
| SG&A expense | $670.00M | $671.00M | $689.00M | $711.00M | $739.00M |
| Operating income | -$131.00M | -$25.00M | $84.00M | $672.00M | $731.00M |
| Pretax income | -$192.00M | -$39.00M | $99.00M | $697.00M | $1.25B |
| Income tax | $26.00M | $61.00M | $64.00M | $186.00M | $191.00M |
| Net income | -$284.00M | -$189.00M | $101.00M | $460.00M | $1.04B |
| EBITDA | $156.00M | $264.00M | $362.00M | $953.00M | $1.01B |
| EPS (basic) | -1.65 | -1.10 | 0.57 | 2.29 | 4.77 |
| EPS (diluted) | -1.65 | -1.10 | 0.57 | 2.27 | 4.72 |
| Dividends declared per share | 0.84 | 1.00 | 0.95 | 0.85 | 0.75 |
| Weighted avg. shares (diluted) | 172.60M | 172.10M | 177.40M | 203.00M | 221.40M |
| Balance sheet | |||||
| Cash & equivalents | $429.00M | $340.00M | $540.00M | $654.00M | $1.04B |
| Inventory | $818.00M | $917.00M | $867.00M | $995.00M | $1.04B |
| Current assets | $2.06B | $2.12B | $2.31B | $3.15B | $3.93B |
| PP&E, net | $2.49B | $2.49B | $2.38B | $2.38B | $2.44B |
| Goodwill | $630.00M | $633.00M | $644.00M | $641.00M | $650.00M |
| Intangibles | $308.00M | $344.00M | $387.00M | $425.00M | $469.00M |
| Total assets | $7.01B | $7.11B | $7.25B | $8.22B | $9.39B |
| Current liabilities | $1.59B | $1.56B | $1.17B | $1.70B | $2.05B |
| Short-term debt | $353.00M | $325.00M | $12.00M | $66.00M | $12.00M |
| Long-term debt | $1.66B | $1.51B | $1.68B | $1.67B | $1.54B |
| Total debt | $2.01B | $1.83B | $1.69B | $1.74B | $1.55B |
| Total liabilities | $4.06B | $3.95B | $3.77B | $4.38B | $4.83B |
| Shareholders' equity | $2.75B | $2.96B | $3.25B | $3.62B | $4.38B |
| Net debt | $1.58B | $1.50B | $1.15B | $1.08B | $509.00M |
| Shares outstanding | 172.62M | 172.14M | 171.58M | 183.63M | 214.17M |
| Cash flow statement | |||||
| Operating cash flow | $289.00M | $263.00M | $209.00M | $914.00M | $952.00M |
| Capital expenditure | $173.00M | $184.00M | $230.00M | $272.00M | $326.00M |
| Free cash flow | $116.00M | $79.00M | -$21.00M | $642.00M | $626.00M |
| Investing cash flow | -$132.00M | -$126.00M | $305.00M | -$279.00M | -$524.00M |
| Financing cash flow | -$76.00M | -$326.00M | -$620.00M | -$994.00M | -$977.00M |
| Depreciation & amortization | $287.00M | $289.00M | $278.00M | $281.00M | $278.00M |
| Stock-based compensation | $31.00M | $30.00M | $28.00M | $29.00M | $30.00M |
| Dividends paid | $146.00M | $174.00M | $169.00M | $171.00M | $159.00M |
| Share buybacks | $0 | $4.00M | $349.00M | $1.00B | $200.00M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.